Search

Your search keyword '"Leonidas C. Platanias"' showing total 545 results

Search Constraints

Start Over You searched for: Author "Leonidas C. Platanias" Remove constraint Author: "Leonidas C. Platanias"
545 results on '"Leonidas C. Platanias"'

Search Results

201. Abstract P3-01-19: HER2-positive circulating tumor cells (CTCs) in advanced breast cancer (BC): A feature independent of BC subtype

202. The Leukemia-associated Mll-Ell Oncoprotein Induces Fibroblast Growth Factor 2 (Fgf2)-dependent Cytokine Hypersensitivity in Myeloid Progenitor Cells

203. TGF-β/Smad3 activates mammalian target of rapamycin complex-1 to promote collagen production by increasing HIF-1α expression

204. Essential Role for the Mnk Pathway in the Inhibitory Effects of Type I Interferons on Myeloproliferative Neoplasm (MPN) Precursors

205. Regulation of the kinase RSK1 by arsenic trioxide and generation of antileukemic responses

206. PD1 and PDL1 upregulation and survival after decitabine treatment in lower risk MDS

207. Relapse of Hodgkin's Disease After 14 Years of Complete Remission

208. Merestinib blocks Mnk kinase activity in acute myeloid leukemia progenitors and exhibits antileukemic effects in vitro and in vivo

209. Discovery and characterization of novel small-molecule CXCR4 receptor agonists and antagonists

210. Dual targeting of eIF4E by blocking MNK and mTOR pathways in leukemia

211. Concordance between genomic alterations assessed by next-generation sequencing in tumor tissue or circulating cell-free DNA

212. Cooperation between AlphavBeta3 integrin and the fibroblast growth factor receptor enhances proliferation of Hox-overexpressing acute myeloid leukemia cells

213. Erratum

214. Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition)

215. Current treatments and future targeted treatments for acute myeloid leukaemia

216. α6β4 Integrin, a Master Regulator of Expression of Integrins in Human Keratinocytes

217. Statin-dependent activation of protein kinase Cδ in acute promyelocytic leukemia cells and induction of leukemic cell differentiation

218. An overview of the mTOR pathway as a target in cancer therapy

219. Abstract PD1-02: Circulating tumor DNA (ctDNA): A real-time application of precision medicine to the management of metastatic breast cancer (MBC)

220. Another tyrosine kinase inhibitor-resistance mutation within the BCR-ABL kinase domain: chasing our tails?

221. Antileukemic effects of AMPK activators on BCR-ABL–expressing cells

222. Dual mTORC2/mTORC1 Targeting Results in Potent Suppressive Effects on Acute Myeloid Leukemia (AML) Progenitors

223. Thymoquinone suppresses growth and induces apoptosis via generation of reactive oxygen species in primary effusion lymphoma

224. Role of Interferon α (IFNα)-inducible Schlafen-5 in Regulation of Anchorage-independent Growth and Invasion of Malignant Melanoma Cells

225. CSIG-15. SLFN5: A REPRESSOR OF INTERFERON-INDUCED SIGNALING THAT STIMULATES GLIOBLASTOMA CELL PROLIFERATION. SURVIVAL RESPONSES IN DIFFERENT XENOGRAFT GLIOBLASTOMA MOUSE MODELS

226. Mechanisms of mRNA translation of interferon stimulated genes

227. Interferon Consensus Sequence Binding Protein (ICSBP) Decreases β-Catenin Activity in Myeloid Cells by Repressing GAS2 Transcription

228. Abstract 5195: Increased circulating tumor cell (CTC) clusters are associated with significantly higher levels of HER2 expression and metastasis in stage III/IV breast cancer

229. Abstract 1597: Increased circulating tumor cell (CTC) after systemic therapy is associated with younger age in stage III/IV breast cancer patients

230. Negative Regulatory Effects of Mnk Kinases in the Generation of Chemotherapy-Induced Antileukemic Responses

231. AMP-activated kinase (AMPK)-generated signals in malignant melanoma cell growth and survival

232. Critical roles for mTORC2- and rapamycin-insensitive mTORC1-complexes in growth and survival of BCR-ABL-expressing leukemic cells

233. Circulating tumor cells enumeration (CTCs) and circulating tumor DNA (ctDNA): Clinical and molecular features of 'rapidly progressing' stage IV disease (Stage IVprog)

234. Dynamic changes of interleukin 2 (IL-2) and circulating tumor cells (CTCs) in patients with advanced breast cancer (BCa) after systemic therapies

235. Glutathione depletion enhances arsenic trioxide-induced apoptosis in lymphoma cells through mitochondrial-independent mechanisms

236. Abstract P2-02-21: The utility and correlation of circulating tumor cells (CTCs) and cell-free circulating tumor DNA (ctDNA) based on HER2 positivity

237. Deregulation of Interferon Signaling in Malignant Cells

238. Type I interferon (IFN)-dependent activation of Mnk1 and its role in the generation of growth inhibitory responses

239. Interferon-Dependent Engagement of Eukaryotic Initiation Factor 4B via S6 Kinase (S6K)- and Ribosomal Protein S6K-Mediated Signals

240. Activation of Protein Kinase Cη by Type I Interferons

241. Protein Kinase C-δ and Phosphatidylinositol 3-Kinase/Akt Activate Mammalian Target of Rapamycin to Modulate NF-κB Activation and Intercellular Adhesion Molecule-1 (ICAM-1) Expression in Endothelial Cells

242. Activation of the p38 Map kinase pathway is essential for the antileukemic effects of dasatinib

243. Inhibition of the TGF-β receptor I kinase promotes hematopoiesis in MDS

244. Curcumin suppresses constitutive activation of nuclear factor-κB and requires functional Bax to induce apoptosis in Burkitt's lymphoma cell lines

245. CCL5-mediated T-cell chemotaxis involves the initiation of mRNA translation through mTOR/4E-BP1

246. Regulation of Arsenic Trioxide-induced Cellular Responses by Mnk1 and Mnk2

247. Suppression of Interferon (IFN)-inducible Genes and IFN-mediated Functional Responses in BCR-ABL-expressing Cells

248. Exploiting the mammalian target of rapamycin pathway in hematologic malignancies

249. Protein kinase C signalling in leukemia

250. Regulatory Effects of Mammalian Target of Rapamycin-mediated Signals in the Generation of Arsenic Trioxide Responses

Catalog

Books, media, physical & digital resources